Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
European Journal of Cancer2011Vol. 47(17), pp. 2592–2602
Citations Over TimeTop 10% of 2011 papers
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro‐omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
Related Papers
- → Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy(2017)73 cited
- → Axitinib in the Treatment of Metastatic Renal Cell Carcinoma(2011)37 cited
- → Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy(2019)16 cited
- Progress in the research of axitinib in the treatment of renal cell carcinoma(2014)